Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype

被引：0

作者：

Lucien Marchand

Arnaud Thivolet

Stéphane Dalle

Karim Chikh

Sophie Reffet

Julien Vouillarmet

Nicole Fabien

Christine Cugnet-Anceau

Charles Thivolet

机构：

[1] Hospices Civils de Lyon,Department of Endocrinology and Diabetes

[2] Lyon-Sud Hospital,Department of Radiology

[3] Hospices Civils de Lyon,Department of Dermatology

[4] Hospices Civils de Lyon,ImmuCare (Immunology Cancer Research)

[5] Lyon-Sud Hospital,Department of Biochemistry

[6] Hospices Civils de Lyon,Department of Immunology

[7] Hospices Civils de Lyon,CarMeN Laboratory (INSERM U1060, INRA U1235, Université Claude Bernard Lyon1, INSA

[8] Lyon-Sud Hospital,Lyon)

[9] Hospices Civils de Lyon,undefined

[10] Lyon-Sud Hospital,undefined

[11] Lyon 1 University,undefined

来源：

Acta Diabetologica | 2019年 / 56卷

关键词：

Diabetes mellitus; Fulminant diabetes; Autoimmune diabetes; Immune checkpoint inhibitors side-effects; Immunotherapy; Programmed cell death-1; Anti-PD-1; Programmed death ligand 1; Anti-PD-L1; Pancreas volume; Beta-cell pancreatic function; Alpha-cell pancreatic function; Exocrine pancreatic function; Mixed meal test;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：441 / 448

页数：7

共 50 条

[31] PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
Jelinek, T.
Hajek, R.
ONCOIMMUNOLOGY, 2016, 5 (12):
[32] Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
Saleh, Khalil
Khalifeh-Saleh, Nadine
Kourie, Hampig Raphael
IMMUNOTHERAPY, 2018, 10 (05) : 345 - 347
[33] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, Pedro Isaacsson
Antonarakis, Emmanuel S.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
[34] A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
Lopez, Adriana T.
Khanna, Trisha
Antonov, Nina
Audrey-Bayan, Claire
Geskin, Larisa
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (06) : 664 - 669
[35] PD-1 and PD-L1 inhibitors in oesophago-gastric cancers
Telli, Tugba Akin
Bregni, Giacomo
Camera, Silvia
Deleporte, Amelie
Hendlisz, Main
Sclafani, Francesco
CANCER LETTERS, 2020, 469 : 142 - 150
[36] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
Sonpavde, Guru
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074
[37] Novel, small molecule inhibitors of PD-1/PD-L1 pathway
Rastelli, Luca
Rajagopal, Sridharan
Gajendran, Chandru
Sadhu, Naveen M.
Mohd, Zainuddin
Gosu, Ramachandraiah
Friedmann-Morvinski, Dinorah
Kandan, Saravanan
Birudukota, Swarnakumari
Srinivasan, S.
Krishnakumar, V
Wahid, Saif
Siddiqui, Amir
Viswakarma, Santosh
Narayan, Ashwini
Rudresh, G.
Mullurwar, Sadanand R.
Sher, Divsha
Mansur, Shahar
Sivanandhan, Dhanalakshmi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[38] PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
Jelinek, Tomas
Mihalyova, Jana
Kascak, Michal
Duras, Juraj
Hajek, Roman
IMMUNOLOGY, 2017, 152 (03) : 357 - 371
[39] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Magiera-Mularz, Katarzyna
Skalniak, Lukasz
Zak, Krzysztof M.
Musielak, Bogdan
Rudzinska-Szostak, Ewa
Berlicki, Lukasz
Kocik, Justyna
Grudnik, Przemyslaw
Sala, Dominik
Zarganes-Tzitzikas, Tryfon
Shaabani, Shabnam
Doemling, Alexander
Dubin, Grzegorz
Holak, Tad A.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
[40] PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Zhang, Ke
Kong, Xiangyi
Li, Yuan
Wang, Zhongzhao
Zhang, Lin
Xuan, Lixue
FRONTIERS IN PHARMACOLOGY, 2022, 13

← 1 2 3 4 5 →